The company has not filed quarterly results since then.
The SEC on Monday also cited the accuracy and adequacy of information on "the identity of the people in charge of the company" as reasons for the halt.
Steven Schwartzbard, chairman of the company's advisory board, said the suspension was in response to pressure from short-sellers.
"We're suffering from a negative side effect caused by our success. That's the only way I can put it," Schwartzbard said in an email to Reuters. "We went public, as virtually all small public companies do, on the over-the-counter market. And everything was fine while the stock sold for $5 or $7.50 a share."
Neuromama's stock had more than quadrupled this year to $56.25 as of its last trade on Aug. 5. The stock's 100-day average volume was 418 shares.
Schwartzbard, who also goes by Vladislav "Steven" Zubkis, also said Neuromama had all intentions to upgrade its listing to Nasdaq.
The company said on Monday it was cooperating with the SEC to ensure the suspension was lifted on Aug. 27.
The SEC previously sued Schwartzbard in 1997 for orchestrating a securities fraud scheme involving boiler-room stock sale techniques.
In 2007, he was sentenced to five years in prison after pleading guilty to charges that he defrauded investors out of $1.8 million in connection with the construction of a storage facility and renovation of a Las Vegas Casino.